/Company Directory

/

Asset Brief

OxiDx

PIQ·Proteomics International Laboratories Ltd·Oxidative stress (diagnostic test; specific clinical indication not yet disclosed)·Preclinical·[ TODO: fill in ]

Plain-language Brief

The trial in plain terms

The disease: Oxidative stress refers to an imbalance between the production of reactive oxygen species and the body's ability to neutralise them with antioxidants. This imbalance has been associated with a range of conditions including cardiovascular disease, diabetes, kidney disease, and neurodegenerative disorders. No single globally standardised diagnostic test for oxidative stress is currently approved for routine clinical use. The specific disease setting that OxiDx is intended to address has not been disclosed in publicly available ASX announcements reviewed for this brief.
What the asset is trying to do: OxiDx is described as a diagnostic device intended to measure oxidative stress, developed by Proteomics International Laboratories Ltd (ASX: PIQ). The underlying biomarkers, assay format, and sample type have not been detailed in the ASX announcements available for this brief. No mechanism-of-action text or target information has been filed for this asset, so further technical detail cannot be confirmed. once company technical disclosures are available.
What the trial is measuring, and why it matters: No clinical trial registration has been identified for OxiDx in publicly available sources reviewed for this brief. As a result, the endpoints, study design, and outcome measures the company intends to use to validate the diagnostic have not been confirmed. once a trial registry record or validation study protocol is publicly disclosed.
Efficacy benchmarks in this setting: Because OxiDx is a diagnostic device rather than a therapeutic, standard therapeutic efficacy benchmarks (response rates, survival data) do not apply directly. Existing research-use oxidative stress assays measure markers such as 8-isoprostane, malondialdehyde, and protein carbonyls; however, no such assay has received regulatory clearance as a standalone clinical diagnostic in Australia or the United States, to the extent determinable from publicly available sources reviewed for this brief. Any early analytical performance figures for OxiDx that may emerge would not be statistically comparable to data from validated, cleared assays given the preclinical stage of this asset.
Commercial context

Trial Design

Design summary

Phase: Preclinical
Design type: [ TODO: fill in ] — no trial registry record identified for this preclinical asset.
Primary endpoint: [ TODO: fill in ]
Key secondary endpoints: [ TODO: fill in ]
Enrolment target: [ TODO: fill in ]
Current enrolment status: [ TODO: fill in ] — asset is preclinical; no enrolment data available.
Sites: [ TODO: fill in ]
Expected readout window: [ TODO: fill in ] — asset is preclinical; no primary completion date is available from trial registry data.

Asset Track Record

Did PIQ deliver against its own guidance?

Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.

8 July 2026regulatory decisionPromarkerEndo USPTO — US patent secured for PromarkerEndohit · positivesrc ASX ↗
21 July 2026regulatory decisionPromarkerEndo Australian commercial launchhit · positivesrc ASX ↗
30 June 2026commercial milestoneUS PromarkerD revenue ramp (CMS reimbursement live Jan 2026)overdue

Class Catalyst Calendar

What's landed, what's next for OxiDx and peers

OxiDx's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for OxiDx. Showing past 6 months and next 12 months · 4 later hidden.

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
Effect of Melatonin on Oxidative Stress Parameters in Levodopa-Treated Parkinson's Disease Patients

Trial design comparison

How OxiDx reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
OxiDx	Proteomics International Laboratories Ltd	Diagnostic Device	Preclinical[ TODO: fill in ]	[ TODO: fill in ] — no trial registry record identified for this preclinical asset.	[ TODO: fill in ]	[ TODO: fill in ]	[ TODO: fill in ]	0
Efficacy of Metformin as an Adjunct to Standard Antidepressant Therapy in Treating Depression Among Obese Patients

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

OtherASX peers ›

33 activeexpand ›

FR
Efficacy of Metformin as an Adjunct to Standard Antidepressant Therapy in Treating Depression Among Obese Patients
Phase 4
Fazaia Ruth Pfau Medical College·Recruiting·Primary completion 1 June 2026·NCT06707012
IM
Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery.

Curated Commentary

Third-party coverage(none curated yet)

expand ›

External analyst notes, journalism, and industry commentary cited with attribution.

No third-party coverage curated for OxiDx yet. Broker coverage of Proteomics International Laboratories Ltd is thin; named analyst notes will appear here as they become available. For now, see the company's ASX announcements and the linked sponsor / class sources elsewhere on this page.

Asset Track Record

Did PIQ deliver against its own guidance?

Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.

8 July 2026regulatory decisionPromarkerEndo USPTO — US patent secured for PromarkerEndohit · positivesrc ASX ↗
21 July 2026regulatory decisionPromarkerEndo Australian commercial launchhit · positivesrc ASX ↗
30 June 2026commercial milestoneUS PromarkerD revenue ramp (CMS reimbursement live Jan 2026)overdue

Class Catalyst Calendar

What's landed, what's next for OxiDx and peers

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
Effect of Melatonin on Oxidative Stress Parameters in Levodopa-Treated Parkinson's Disease Patients

Trial design comparison

How OxiDx reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
OxiDx	Proteomics International Laboratories Ltd	Diagnostic Device	Preclinical[ TODO: fill in ]	[ TODO: fill in ] — no trial registry record identified for this preclinical asset.	[ TODO: fill in ]	[ TODO: fill in ]	[ TODO: fill in ]	0
Efficacy of Metformin as an Adjunct to Standard Antidepressant Therapy in Treating Depression Among Obese Patients

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

OtherASX peers ›

33 activeexpand ›

FR
Efficacy of Metformin as an Adjunct to Standard Antidepressant Therapy in Treating Depression Among Obese Patients
Phase 4
Fazaia Ruth Pfau Medical College·Recruiting·Primary completion 1 June 2026·NCT06707012
IM
Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery.

OxiDxn = 0

Proteomics International Laboratories Ltd·Diagnostic Device·Preclinical·[ TODO: fill in ]

Design: [ TODO: fill in ] — no trial registry record identified for this preclinical asset.
Primary endpoint: [ TODO: fill in ]
Dosing: [ TODO: fill in ]
Eligibility: [ TODO: fill in ]

Efficacy of Metformin as an Adjunct to Standard Antidepressant Therapy in Treating Depression Among Obese Patientsn = —

Fazaia Ruth Pfau Medical College·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery.n = —

Instituto Mexicano del Seguro Social·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Efficacy of NOSHINtrial in Diabetic Patientsn = —

Kerman Medical University·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Vericiguat and Reverse Remodeling Indices in Heart Failuren = —

University Medical Centre Ljubljana·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplastyn = —

Vanderbilt University Medical Center·—·Phase 4

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Effect of Low-Dose Versus High-Dose Alpha-Lipoic Acid on Oxidative Stress, Inflammation, and Clinical Outcomes in Acute Exacerbations of Chronic Obstructive Pulmonary Diseasen = —

Ain Shams University·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Dalargin for Prevention of Organ Disfunction in High-Risk Abdominal Surgeryn = —

Botkin Hospital·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brainn = —

Universidad de Almeria·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Improving Mobility After Revascularization in Peripheral Artery Diseasen = —

Northwestern University·—·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Preventing Systemic Inflammation After Cardiac Surgery With Alkaline Phosphatasen = —

Alloksys Life Sciences B.V.·—·PHASE2/PHASE3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Gut Microbiome Profiles in Patients with Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544).n = —

Bernardino Clavo, MD, PhD·—·PHASE2/PHASE3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathyn = —

Bernardino Clavo, MD, PhD·—·PHASE2/PHASE3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKDn = —

University of Colorado, Denver·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markersn = —

Susanne Arnold·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Biological Effects of Quercetin in COPD Phase IIn = —

Temple University·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Black Seed Oil in ADHDn = —

Ain Shams University·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Efficacy and Safety of Black Seed Oil With Vonoprazan Based Triple Therapy in Treatment of Helicobacter Pylorin = —

Ain Shams University·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Cilostazol in Parkinson's Diseasen = —

Ain Shams University·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Supplementation for Male Subfertilityn = —

Hamilton Health Sciences Corporation·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophyn = —

Massachusetts Eye and Ear Infirmary·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Effect of Melatonin on Oxidative Stress Parameters in Levodopa-Treated Parkinson's Disease Patientsn = —

Bangladesh Medical University·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

The Efficacy of Tocotrienol Rich Fraction for Liver Protection in Adult Patients With Alcoholic Fatty Liver Disease (AFLD)n = —

Universiti Kebangsaan Malaysia Medical Centre·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDHn = —

Coordinación de Investigación en Salud, Mexico·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenian = —

China Medical University Hospital·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Monotherapy of an NMDA Enhancer for Schizophrenian = —

China Medical University Hospital·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Effects of an Antioxidant Supplement on Blood Vessel Healthn = —

University of Georgia·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

2-HOBA in Systemic Lupus Erythematosusn = —

Vanderbilt University Medical Center·—·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americansn = —

Vanderbilt University Medical Center·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ESn = —

Texas Tech University Health Sciences Center·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Impact of Chromium Supplementation on Glucido-lipidic Metabolism, Oxidative Stress and Inflammatory State in Patients with Gestational Diabetesn = —

University of Kasdi Merbah·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Double-blind Pilot Study on the Effect of Anionic Exposome Enrichment (Biow) on Recovery and Sleep Quality in Postoperative Patientsn = —

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Adia MED of Winter Park LLC Autism Spectrum Disorder Research Studyn = —

Adia Med of Winter Park LLC·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Relaxin Therapy for Atrial Fibrillationn = —

Deeptankar DeMazumder·—·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —